Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.
1. A method of reducing inflammation in a human subject, comprising administering to the subject a pharmaceutical composition comprising Blautia hydrogenotrophica , such that inflammation in the subject is reduced.
2. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
3. The method of claim 1 , wherein the subject has an autoimmune or inflammatory disorder.
4. The method of claim 3 , wherein the autoimmune or inflammatory disorder is selected from the group consisting of an inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, multiple sclerosis (MS), systemic lupus erythematosus (SLE), type I diabetes, rheumatoid arthritis, Sjögren's syndrome, and Celiac disease.
5. The method of claim 1 , wherein administration of the pharmaceutical composition reduces inflammation in the gastrointestinal tract of the subject.
6. The method of claim 1 , wherein administration of the pharmaceutical composition at a first site reduces inflammation at a distal site in the subject.
7. The method of claim 6 , wherein the distal site is blood, skin, vagina, liver, spleen, fallopian tubes, uterus, or a combination thereof.
8. The method of claim 1 , wherein the subject has a dysbiosis.
9. The method of claim 8 , wherein the dysbiosis is a gastrointestinal dysbiosis.
10. The method of claim 8 , wherein the dysbiosis is a distal dysbiosis.
11. The method of claim 1 , wherein the administration of the pharmaceutical composition decreases secretion of pro-inflammatory cytokines by human peripheral blood mononuclear cells (PBMCs), or increases secretion of anti-inflammatory cytokines by human PBMCs, or decreases secretion of pro-inflammatory cytokines by human PBMCs and increases secretion of anti-inflammatory cytokines by human PBMCs.
12. The method of claim 11 , wherein the administration of the pharmaceutical composition decreases secretion of a pro-inflammatory cytokine selected from the group consisting of IFNγ, IL-12p70, IL-1α, IL-6, IL-8, MCP1, MIP1α, MIP1β, TNFα, and combinations thereof.
13. The method of claim 11 , wherein the administration of the pharmaceutical composition increases secretion of an anti-inflammatory cytokine selected from the group consisting of IL-10, IL-13, IL-4, IL-5, TGFβ, and combinations thereof.
14. The method of claim 1 , wherein the level of Blautia hydrogenotrophica is augmented in the gastrointestinal tract of the subject.
15. The method of claim 14 , wherein the Blautia hydrogenotrophica engraft in the gastrointestinal tract of the subject.
16. The method of claim 1 , wherein the level of the bacteria is augmented at a site distal to the site of administration in the subject.
17. The method of claim 16 , wherein the bacteria is not detectably present at the site distal to the gastrointestinal tract of the subject prior to administration of the pharmaceutical composition.
18. The method of claim 16 , wherein the bacteria translocate to a distal site within the subject.
19. The method of claim 16 , wherein the site distal to the gastrointestinal tract is the blood, skin, vagina, liver, spleen, fallopian tubes, uterus, or a combination thereof.
20. The method of claim 1 , wherein the level of a bacterial species not present in the pharmaceutical composition is augmented in the gastrointestinal tract of the subject.
21. The method of claim 1 , wherein the level of a bacterial species not present in the pharmaceutical composition is augmented at a site distal to the gastrointestinal tract of the subject.
22. The method of claim 21 , wherein the site distal to the gastrointestinal tract is the blood, skin, vagina, liver, spleen, fallopian tubes, uterus, or a combination thereof.
23. The method of claim 1 , further comprising administering a prebiotic to the subject.
24. The method of claim 23 , wherein the prebiotic augments the growth of the bacterial population present in the pharmaceutical composition.
25. The method of claim 23 , wherein the prebiotic comprises a monomer or polymer selected from the group consisting of arabinoxylan, xylose, soluble fiber dextran, soluble corn fiber, polydextrose, lactose, N-acetyl-lactosamine, glucose, and combinations thereof.
26. The method of claim 23 , wherein the prebiotic comprises a monomer or polymer selected from the group consisting of galactose, fructose, rhamnose, mannose, uronic acids, 3′-fucosyllactose, 3′ sialylactose, 6′-sialyllactose, lacto-N-neotetraose, 2′-2′-fucosyllactose, and combinations thereof.
27. The method of claim 23 , wherein the prebiotic comprises a monosaccharide selected from the group consisting of arabinose, fructose, fucose, lactose, galactose, glucose, mannose, D-xylose, xylitol, ribose, and combinations thereof.
28. The method of claim 23 , wherein the prebiotic comprises a disaccharide selected from the group consisting of xylobiose, sucrose, maltose, lactose, lactulose, trehalose, cellobiose, and combinations thereof.
29. The method of claim 23 , wherein the prebiotic comprises a polysaccharide, wherein the polysaccharide is xylooligosaccharide.
30. The method of claim 1 , wherein the pharmaceutical composition comprises only one bacterial species.